Related by context. All words. (Click for frequent words.) 76 refractory PTCL 74 refractory chronic lymphocytic 72 relapsed refractory multiple myeloma 71 refractory peripheral T 71 refractory multiple myeloma 70 refractory systemic ALCL 70 dasatinib Sprycel ® 68 cutaneous T cell 68 lymphoma CTCL 68 refractory AML 68 relapsed multiple myeloma 68 oral ridaforolimus 68 Amrubicin 68 sorafenib tablets 68 refractory acute myeloid 68 refractory cutaneous T 67 PDX pralatrexate 67 Phase #b/#a clinical 67 systemic anaplastic large 67 FOLOTYN 67 metastatic GIST 67 MAGE A3 ASCI 67 FOLOTYN ® 67 cell lymphoma CTCL 66 phase IIb clinical 66 cutaneous T 66 Cloretazine ® 66 refractory CTCL 66 refractory acute promyelocytic 66 Stedivaze 66 TELCYTA 66 alvimopan 66 PNP inhibitor 66 alvespimycin 66 receptor tyrosine kinase inhibitor 66 rALLy clinical trial 65 Nexavar ® 65 Orphan Drug designations 65 refractory APL 65 Allovectin 7 ® 65 brentuximab vedotin SGN 65 refractory CLL 65 Panzem R 65 Soliris TM eculizumab 65 radiation sensitizer 65 BiovaxID TM 65 Personalized Immunotherapy 65 forodesine 65 refractory indolent non 65 refractory metastatic colorectal cancer 65 Fibrillex TM 65 unique alkylating agent 65 ZOLINZA 65 OncoVEX GM CSF 65 Cloretazine 65 targeted radiotherapeutic 65 Panzem R NCD 65 opioid induced constipation OIC 65 relapsed SCLC 65 OPAXIO 65 nilotinib Tasigna ® 64 recurrent NSCLC 64 R sorafenib tablets 64 pseudobulbar affect PBA 64 Icatibant 64 advanced metastatic renal 64 VIVITROL ® 64 Onrigin TM 64 Tamibarotene 64 ganetespib 64 refractory ALCL 64 dasatinib Sprycel 64 CYT# potent vascular disrupting 64 Raptiva ® 64 LymphoStat B belimumab 64 gastrointestinal stromal tumors 64 Ceflatonin 64 prGCD 64 Zelrix 64 candidate brentuximab vedotin 64 refractory NSCLC 64 PrevOnco 64 Elagolix 64 Zenvia ™ 64 TRISENOX ® 64 TREANDA 64 non metastatic osteosarcoma 64 ADVEXIN p# therapy 64 generation purine nucleoside 64 #D#C# 64 bevacizumab Avastin ® 64 ezogabine 64 ospemifene 64 biologic therapy 64 Cinryze TM 63 YONDELIS 63 sunitinib malate 63 tanespimycin 63 forodesine hydrochloride 63 AP# [003] 63 systemic ALCL 63 B CLL 63 systemic ALCL patients 63 SILENOR TM 63 Traficet EN 63 Allovectin 7 63 CTAP# Capsules 63 MyVax R 63 Onrigin 63 Ophena TM 63 Plenaxis TM 63 leukemia APL 63 HGS ETR1 63 Arzerra ofatumumab 63 platinum refractory 63 chronic angina 63 pralatrexate 63 Ceflatonin R 63 Xanafide 63 ponatinib 63 unresectable 63 Targretin capsules 63 metastatic CRC 63 HGS ETR2 63 autologous cellular immunotherapy 63 ILUVIEN ® 63 TORISEL 63 Cloretazine R VNP#M 63 RhuDex ® 63 Dacogen injection 63 gastrointestinal stromal tumors GIST 63 Perifosine 63 OMAPRO 63 2 methoxyestradiol 63 erlotinib Tarceva ® 63 lintuzumab SGN 63 Civacir 63 hereditary deficiency 63 evaluating Xcytrin 63 Iluvien ® 63 temsirolimus Torisel ® 63 Peginterferon alfa 2b 63 myelofibrosis 63 Pivotal Phase III 63 Clolar ® 63 glufosfamide 63 Phenoptin 63 acyclovir Lauriad R 63 Ceplene 63 Wafer polifeprosan 63 LEUKINE 63 Li Fraumeni Syndrome 63 Cutaneous T 63 Intravenous CP 63 DAVANAT 62 induced macular edema 62 refractory HL 62 TYKERB 62 maribavir 62 SNT MC# 62 Campath ® 62 BYETTA ® 62 ALN TTR 62 Ixempra 62 Combidex 62 registrational 62 HGS# 62 HER2 positive metastatic breast 62 Gemzar ® 62 PANVAC VF 62 refractory systemic anaplastic 62 imatinib resistant 62 delivers fluocinolone acetonide FA 62 leukemia CLL 62 azacitidine 62 Pemetrexed 62 EGFR expressing mCRC 62 PHX# 62 Nimotuzumab 62 Pegloticase 62 bendamustine 62 IMA# 62 Tarceva TM 62 Allovectin 7 R 62 OMNARIS HFA 62 VPRIV 62 ixabepilone 62 IMiDs 62 refractory myeloma 62 TRIOLEX HE# APOPTONE HE# 62 drug ISA# 62 dextromethorphan quinidine 62 tumors GIST 62 mGluR5 negative 62 dirucotide MBP# 62 gastrointestinal stromal tumor GIST 62 Genasense ® 62 brentuximab vedotin 62 BENLYSTA 62 Bortezomib 62 MOZOBIL 62 orphan medicinal product 62 axitinib 62 Certican 62 post herpetic neuralgia PHN 62 tezampanel NGX# 62 LibiGel ® 62 metastatic renal cell carcinoma 62 Lenalidomide 62 intravenous methylnaltrexone 62 Pirfenidone 62 EOquin 62 Cellegesic 62 MYLOTARG 62 HuMax CD4 62 SPRYCEL ® 62 anticancer compound 62 PROVENGE ® 62 Azedra 62 investigational therapies 62 elacytarabine 62 mTOR kinase 62 EOquin TM 62 Diabetic Macular Edema 62 Insegia 62 TELINTRA 62 ADVEXIN 62 severe gastroparesis 62 oral proteasome inhibitor 62 KRN# 62 stage IIIB 62 Vidaza R 62 histone deacetylase HDAC inhibitor 62 Archexin 62 TRISENOX 62 tezampanel 62 modified glutathione analog 62 INCB# [001] 62 OvaRex ® MAb 62 Omacetaxine 62 Alemtuzumab 62 temsirolimus 62 XL# anticancer compounds 62 lintuzumab 62 phase Ib 62 eltrombopag 62 Orphan Drug 62 Fast Track designations 62 registrational trial 62 intravesical infusion therapy 62 5 lipoxygenase inhibitor 62 metastatic malignant 62 evaluating tivozanib 62 Hsp# Inhibitor 62 Gel repository corticotropin injection 62 GATTEX ® 62 novel VDA molecule 62 pancreatic NET 62 TBC# 62 Annamycin 61 AA amyloidosis 61 BENLYSTA ® 61 SinuNase TM 61 Entereg R 61 vandetanib 61 CINQUIL 61 KNS # 61 SUTENT 61 castrate resistant prostate cancer 61 fluoropyrimidine 61 TEMODAL 61 Plenaxis R 61 ALN PCS 61 ZADAXIN ® 61 lenalidomide Revlimid R 61 IL# PE#QQR 61 valopicitabine 61 Bezielle 61 myelodysplastic syndromes 61 Clofarabine 61 visilizumab 61 severe hypercholesterolemia 61 dependent kinase inhibitor 61 Evoltra ® 61 taliglucerase alfa 61 BAY #-# 61 plus prednisone prednisolone 61 Marqibo 61 Ceflatonin ® 61 pegfilgrastim 61 tamibarotene 61 herpetic keratitis 61 ularitide 61 Torisel 61 Nabi HB Intravenous 61 cell chronic lymphocytic 61 Plicera 61 biliary tract cancer 61 L MTP PE 61 Actemra tocilizumab 61 Exelixis compounds 61 primary hypercholesterolemia 61 BrachySil 61 Glufosfamide 61 docetaxel Taxotere ® 61 PREOS 61 talactoferrin 61 Onalta ™ 61 Azilect ® 61 Virulizin ® 61 Oral NKTR 61 PXD# 61 xanthine oxidase inhibitor 61 TAFA# 61 TYZEKA 61 REPLAGAL 61 highly purified pasteurized 61 AVASTIN 61 sorafenib Nexavar ® 61 oral rivaroxaban 61 Troxatyl 61 LymphoStat B 61 vosaroxin 61 Navelbine ® 61 dose escalation phase 61 remission induction 61 trabectedin 61 Xyrem ® 61 Perifosine KRX 61 PEG PAL 61 oral picoplatin 61 Aflibercept 61 reslizumab 61 TRANSDUR ® 61 forodesine HCl 61 UPLYSO 61 mapatumumab 61 mRCC 61 galiximab 61 dirucotide 61 clofarabine 61 Cannabinor 61 metastatic colorectal 61 personalized cellular immunotherapy 61 rALLy trial 61 Zavesca r 61 Cinryze ™ 61 INC# 61 PEGINTRON TM 61 metastatic HRPC 61 sodium Injection 61 Fludara 61 EFAPROXYN 61 recurrent glioblastoma multiforme 61 Clolar 61 Cladribine Tablets 61 unresectable recurrent 61 include Phenoptin TM 61 ONCASPAR 61 R lenalidomide 61 cUTI 61 novel histone deacetylase 61 Vidaza ® 61 PREZISTA r 61 MGCD# [001] 61 Genasense R 61 CIMZIA ™ 61 refractory gout 61 Combination REOLYSIN R 61 vemurafenib 61 amrubicin 61 Alzhemed TM 61 Voreloxin 61 evaluating picoplatin 61 anthracycline taxane 61 oral prodrug 61 Dalbavancin 61 recurrent metastatic ovarian cancer 61 pegylated interferons 61 Vidaza azacitidine 61 Vimpat R 61 PI3K/Akt pathway inhibitor 61 virus HCV protease inhibitor 61 vascular disrupting agent 61 AEG# 61 riociguat 61 Solazed TM 61 ZEVALIN ® 61 Triapine 61 brostallicin 61 opioid induced constipation 60 Fludara ® 60 rALLy 60 Ranexa R 60 AzaSite Plus 60 mGluR5 NAM 60 Advanced Renal Cell 60 leukemia AML 60 Ambrisentan 60 diabetic neuropathic pain 60 corticotropin injection 60 cetuximab Erbitux R 60 cetuximab Erbitux ® 60 IV acetaminophen 60 pediatric Crohn disease 60 investigational antiplatelet agent 60 briakinumab 60 DOXIL 60 oral FTY# 60 Seliciclib 60 imatinib Gleevec ® 60 myelodysplastic syndromes MDS 60 Inhalation Solution 60 sulodexide 60 Vicinium TM 60 Daclizumab 60 systemic fungal infections 60 sorafenib Nexavar 60 metaglidasen 60 Æterna Zentaris 60 picoplatin 60 mTOR inhibitor 60 romidepsin 60 T#I mutation 60 Onco TCS 60 ruxolitinib 60 Solzira TM 60 RANK Ligand inhibitor 60 subcutaneous formulation 60 diarrhea predominant irritable 60 Actimmune ® 60 schizophrenia CIAS 60 EDEMA3 60 PEGylated anti 60 ongoing Phase 1b 60 orBec 60 elotuzumab 60 Pixantrone 60 albinterferon alfa 2b 60 thymalfasin 60 ONTAK 60 GATTEX ™ 60 XL# XL# 60 BrachySil TM 60 pain palliation 60 relapsed acute myelogenous 60 VEGFR2 inhibitor 60 Azixa 60 Granted Orphan Drug 60 VELCADE melphalan 60 AeroLEF TM 60 CoFactor 60 Sudhir Agrawal D.Phil 60 TRANSDUR ™ 60 investigational pan BCR 60 Velcade bortezomib 60 relapsing multiple sclerosis 60 orally administered inhibitor 60 FDA Orphan Drug 60 Silodosin 60 Xyfid TM 60 cell carcinoma RCC 60 voreloxin 60 Linjeta TM 60 Hepatocellular Carcinoma HCC 60 IRESSA 60 Pralatrexate 60 ferumoxytol Injection 60 Phase Ib IIa 60 Oracea TM 60 overactive bladder AA# 60 Lenocta TM 60 GSK# [001] 60 IV NSCLC 60 GAMMAGARD 60 candidate NGX 60 trastuzumab DM1 T DM1 60 HCV SPRINT 60 relapsing remitting MS RRMS 60 Vandetanib 60 mitogen activated ERK kinase 60 Aryplase 60 Meets Primary Endpoint 60 investigational pharmacologically unique 60 ATryn R 60 calcineurin inhibitors 60 MAA submission 60 FACTIVE tablets 60 COMFORT II 60 Yondelis ® 60 ORENCIA ® 60 ELOXATIN 60 protease inhibitor PI 60 sargramostim 60 confirmatory Phase III 60 chronic myocardial ischemia 60 non squamous NSCLC 60 non squamous 60 Alocrest 60 LEVADEX TM 60 markets HP Acthar 60 EGFR expressing metastatic colorectal 60 Rhucin ® 60 EGFR TKI 60 Study GL# 60 palifosfamide 60 GATTEX TM 60 carcinoma HCC 60 MYDICAR ® 60 Prestara 60 methylnaltrexone bromide 60 castration resistant prostate cancer 60 posaconazole 60 Proxinium TM 60 Carfilzomib 60 myelodysplastic myeloproliferative diseases 60 Kit CD# positive 60 Anturol TM 60 TLK# 60 HP Acthar Gel repository 60 AVONEX ® 60 ALN VSP 60 catheter occlusion 60 metastatic colorectal cancer 60 Phase 2a trial 60 metastatic castrate resistant 60 Loramyc R 60 allogeneic stem cell 60 ORENCIA R 60 Irinotecan 60 successfully commercialize Iluvien 60 unresectable liver cancer 60 Prestara TM 60 HuMax EGFr 60 heavily pretreated 60 prostate cancer HRPC 60 myelodysplastic syndrome MDS 60 liposomal formulation 60 small molecule Hedgehog 60 SUCCEED trial 60 PROVENGE sipuleucel T 60 Zingo TM 60 cinacalcet HCl 60 Aviptadil 60 FOLFOX6 chemotherapy regimen 60 evaluating REVLIMID 60 CORTOSS 60 Xeloda ® 60 Myelofibrosis 60 Gleevec resistant 60 relapsed refractory 60 IMGN# 60 Azedra TM 60 Amigal TM 60 XIAFLEX ™ 60 pertuzumab 60 TOCOSOL Paclitaxel 60 candidates Azedra TM 60 thalidomide Thalomid 60 HYVISC R 60 ZYBRESTAT fosbretabulin 60 bortezomib Velcade 60 FENTORA 60 kidney urologic 60 Application BLA 60 metastatic malignant melanoma 60 dasatinib 60 VNP#M 60 lymphoid malignancies 60 relapsed MM 60 MGd 60 novel emulsion formulation 60 AEGR 60 GALNS 60 Xcellerated T Cells 60 refractory DLBCL 60 lucinactant 60 post operative ileus 60 LUMINATE 60 Phase IIIb clinical 60 metastatic renal cell 60 Acute Myeloid Leukemia AML 60 Zenvia TM 60 abatacept Orencia 60 Tekamlo 60 ISENTRESS 60 hypoparathyroidism 60 Pixuvri 60 recurrent GBM 60 ribavirin RBV 60 NeuroStar TMS Therapy 60 Increlex ® 60 Increlex R 60 phase IIa clinical 60 Vilazodone 59 Phase III Pivotal 59 Bendamustine 59 Clevudine 59 AAG geldanamycin analog 59 carfilzomib 59 dacarbazine DTIC 59 cytotoxic chemotherapy 59 GTC recombinant human 59 IV metastatic melanoma 59 interferon gamma 1b 59 cangrelor 59 Zerenex 59 gemcitabine cisplatin 59 myelofibrosis polycythemia vera 59 candidate deforolimus 59 cediranib 59 active comparator 59 Phase Ib study 59 JOULFERON 59 Tyrima 59 fallopian tube cancers 59 including eniluracil ADH 59 Romiplostim 59 multiple myeloma MM 59 Tibotec Therapeutics division 59 Mepact 59 liver resection surgeries 59 Corlux 59 Neulasta R 59 Silenor ® 59 adult chronic ITP 59 Fodosine 59 doxorubicin HCl liposome injection 59 proteasome inhibitor 59 XIAFLEX ® 59 phase IIb trial 59 OMNARIS Nasal Spray 59 unresectable malignant mesothelioma UMM 59 6R BH4 59 acetonide FA 59 Taxotere ® 59 Quinamed 59 NYHA Class II 59 CDK cyclin dependent 59 Phase 2b clinical 59 sapacitabine 59 Dapagliflozin 59 hematological malignancies 59 Bicifadine 59 dacarbazine 59 Qutenza TM 59 Cleviprex TM clevidipine 59 trastuzumab Herceptin ® 59 ELADUR ™ 59 Fx #A 59 INT# [002] 59 synthetic retinoid 59 non alcoholic steatohepatitis 59 assessing T DM1 59 dacetuzumab 59 dextofisopam 59 efalizumab 59 AQ4N 59 previously untreated follicular 59 molecular imaging radiopharmaceutical 59 Selzentry Celsentri 59 ATryn ® 59 MEK Inhibitor 59 Ozarelix 59 Orphan Drug status 59 chronic ITP patients 59 perifosine 59 Ventavis 59 Tasimelteon 59 SCIg 59 sNDA submission 59 Amigal 59 SCH # 59 ara C 59 BRIM3 59 HuLuc# 59 MERLIN TIMI 59 Dasatinib 59 ThermoDox R 59 candidate XP# 59 esophageal candidiasis 59 eribulin mesylate 59 BEXXAR 59 CCX# 59 RAPTIVA 59 sunitinib Sutent ® 59 alpha folate receptor 59 ISTODAX 59 ALGRX 59 monoclonal antibody conjugated 59 XYOTAX TM 59 Rebif ® 59 phase III isavuconazole 59 sodium glucose cotransporter 59 irinotecan containing 59 tocilizumab 59 TKI therapy 59 imatinib mesylate 59 TheraCIM 59 Herceptin trastuzumab 59 refractory rituximab naive 59 OvaRex R 59 Somatuline R Autogel R 59 boosted protease inhibitor 59 cognitive impairment associated 59 GRN# 59 everolimus tablets 59 Androxal ® 59 CIMZIA TM 59 Pivotal Trial 59 Pegasys ® 59 Ketotransdel TM 59 K ras mutations 59 investigational monoclonal antibody 59 romiplostim 59 vernakalant hydrochloride 59 oxymorphone ER 59 Trastuzumab 59 FIRAZYR 59 Besivance 59 individualized cellular immunotherapy 59 HCD# [002] 59 Golimumab 59 tafamidis 59 Orphan Status 59 metastatic castration resistant 59 depressive episodes associated 59 Dabigatran etexilate 59 Belimumab 59 Poly ICLC 59 L BLP# 59 Leukine ® 59 TMS Therapy 59 ABL inhibitor 59 FUSILEV ® 59 thetreatment 59 IRX 2 59 obatoclax 59 Ganite ® 59 Talabostat 59 metastatic carcinoid 59 MEPACT 59 fosbretabulin 59 Tasigna nilotinib 59 chronic myeloid leukemia CML 59 Vorinostat 59 SUTENT ® 59 Hedgehog Pathway Inhibitor 59 FavId 59 Naproxcinod 59 cisplatin gemcitabine 59 Pivotal Phase 59 alkylating agent 59 Zolinza 59 Vaprisol 59 Darinaparsin 59 Ceplene R 59 BRIM2 59 Tanespimycin 59 Copegus ribavirin 59 granted Ortec 59 huN# DM1 59 infusional 5-FU/LV 59 JAK inhibitor 59 AGGRASTAT R 59 Ketotransdel 59 Gliadel Wafer 59 bardoxolone 59 paliperidone palmitate 59 CBLC# 59 systemic immunosuppressive drugs 59 refractory metastatic 59 standard chemotherapy regimens 59 CEQ# 59 GVAX Pancreas Vaccine 59 pegylated interferon alpha 59 JAK2 inhibitor 59 Auxilium transmucosal film 59 RSR# 59 histamine dihydrochloride 59 Randomized Phase II 59 hematologic malignancies 59 Bevacizumab 59 ACTEMRA TM 59 sapacitabine CYC# 59 AIR CF1 59 Bayer HealthCare Onyx Pharmaceuticals 59 Vivaglobin 59 custirsen 59 lupus nephritis 59 multicenter Phase III 59 SILENOR 59 pancreatic neuroendocrine tumors 59 Genasense 59 alpha 2b 59 SYCREST 59 IAP inhibitor 59 Jevtana 59 BCG refractory carcinoma 59 BR.# 59 Tarceva erlotinib 59 Q#IR 59 velaglucerase alfa 59 SomatoKine 59 Chronic Idiopathic Constipation 59 XYOTAX 59 Nexavar sorafenib 59 tolevamer 59 oxaliplatin Eloxatin 59 Bronchitol 59 carcinoma mCRC 59 QuadraSphere 59 REVLIMID R 59 metastatic hormone refractory 59 SAPHRIS 59 tubulin inhibitor 59 Renal Cell Carcinoma RCC 59 neratinib 59 refractory prostate cancer 59 Pyridorin 59 atypical Hemolytic Uremic Syndrome 59 rasagiline tablets 59 IIa trial 59 gemcitabine carboplatin 59 R#/MEM # 59 idiopathic pulmonary fibrosis IPF 59 diagnostic molecular imaging 59 indolent NHL 59 cSSSI 59 mifamurtide 59 CB2 selective receptor agonist 59 CLARITY study 59 OMP designation 59 enzastaurin 59 Abilify aripiprazole 59 eculizumab 59 omacetaxine mepesuccinate 59 Zorbtive TM 59 subependymal giant cell 59 docetaxel Taxotere R 59 TM pralatrexate injection 59 Romidepsin 59 refractory angina 59 pharmacokinetic PK study 59 Zemplar Capsules 59 telbivudine 59 polymerase inhibitor 59 REVLIMID lenalidomide 59 Taxotere R 59 IoGen 59 mocetinostat MGCD# 59 oncology indications 59 rilonacept 59 fluvoxamine maleate 59 R bendamustine hydrochloride 59 Silenor ® doxepin 59 tiuxetan 59 antimetabolite 59 topically applied SEPA 59 MOVIPREP R 59 TTF Therapy 59 Somatuline Depot 58 Rituxan rituximab 58 ELACYT 58 R roscovitine 58 hyperuricemia 58 Phase 2b study 58 BEMA Buprenorphine 58 Cloretazine R 58 TRO# 58 Onalta 58 Dyloject TM 58 refractory follicular lymphoma 58 constipation OIC 58 Cotavance 58 non splenectomized 58 lorvotuzumab mertansine 58 satraplatin 58 carcinoid syndrome 58 ZEVALIN 58 transthyretin mediated amyloidosis ATTR 58 recurrent ovarian cancer 58 Marketing Authorization Application 58 interferon beta therapy 58 G#DT 58 BCG refractory 58 hoFH 58 zalutumumab 58 DORIBAX 58 Brentuximab Vedotin SGN 58 Genasense R oblimersen 58 VISICOL R 58 Tekturna HCT 58 selective modulator 58 doripenem 58 Augment TM 58 CCR5 antagonist 58 androgen independent 58 Keppra ® levetiracetam 58 INVANZ 58 Tiuxetan 58 adalimumab Humira 58 Friedreich Ataxia FRDA 58 hepatocellular cancer 58 cancer neuroendocrine tumor 58 PIX# [002] 58 Refractory Hodgkin Lymphoma 58 Pazopanib 58 TAXUS Element Stent System 58 Octreolin 58 R roscovitine CDK cyclin 58 dimebon 58 Myocet 58 Exherin TM 58 torezolid phosphate 58 OMAPRO ™ 58 Refractory Peripheral T 58 Orphan Medicinal Product 58 allosteric modulator NAM 58 CR# vcMMAE 58 candidate AQ4N 58 Pimavanserin 58 THALOMID 58 ZYBRESTAT 58 FRDA 58 placebo controlled clinical 58 IV APAP 58 invasive candidiasis 58 gefitinib Iressa 58 confirmatory Phase 3 58 AA Amyloidosis 58 Serdolect ® 58 opioid naive 58 MabThera Rituxan 58 refractory colorectal cancer 58 Mylotarg 58 sarcoma melanoma 58 Orathecin 58 Dementia Related Psychosis 58 dexanabinol 58 Cimzia TM 58 Sebivo 58 Phase Ib 58 developing Bicifadine serotonin 58 pomalidomide 58 Crofelemer budesonide foam 58 Panzem NCD 58 nilotinib 58 INCB# [002] 58 ADVEXIN clinical 58 ONCONASE 58 Virulizin R 58 SUPPRELIN R LA 58 epigenetic therapies 58 chemotherapy induced neutropenia 58 metastatic RCC 58 Treatment IND 58 relapsed ovarian cancer 58 IPLEX 58 pan HDAC inhibitor 58 RoACTEMRA 58 GED aPC 58 sodium thiosulfate STS 58 R vitespen 58 Trofex 58 novel oral anticoagulant 58 lumiliximab 58 TRISENOX R 58 STEDESA 58 Ocrelizumab 58 lexidronam injection 58 SEROQUEL 58 Ganite R 58 CINTREDEKIN BESUDOTOX 58 HRPC 58 treat chronic sinusitis 58 Kamada AAT 58 XL# XL# XL# XL# 58 palifermin 58 PRTX 58 MyVax ® 58 D aspartate NMDA receptor 58 dose escalation clinical 58 PREOS R 58 investigational immunotherapy 58 registrational Phase 58 vinorelbine 58 Neo Urinary Conduit 58 Phase Ib clinical trials 58 topical NSAID 58 relapsing remitting multiple sclerosis 58 diagnostic radiopharmaceutical 58 KIACTA ™ 58 evaluating satraplatin 58 RRMS patients 58 ZADAXIN 58 CCX# B 58 CTCL 58 hormone refractory metastatic prostate